Chronic lymphocytic leukaemia: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• BTK 26
• CD19 33
• BCL-2 10
• TP53 3
• CD20 10
• CD22 6
• ABL1 2
• PI3K 1
• NOTCH1 0
• CXCR4 0
• STAT3 0
• CD123 1
• CD38 1
• HMGB1 0
• PD-1 0
• PD-L1 0
• EGFR 0
• HDAC 0
• MDM2 0
• PPAR 0
• TIM-3 0
• AKT 0
• ALK 0
• ATM 0
• BCMA 1
• BDNF 0
• BRAF 0
• BRD4 0
• CD30 0
• CD47 0
• CSF1R 1
• CTNNB1 0
• ERK 0
• FAK 0
• FLT3 0
• IDH 0
• IL-23 0
• IL-4 0
• KMT2A 0
• MAPK 0
• MMP-9 0
• NLRP3 0
• NRAS 0
• PCSK9 0
• PRMT5 0
• TLR4 0
• VEGF 0

24 of 58+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Signaling and Powering Anti-cancer Responses in T Cells SPARC

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €2,500,000· until Oct 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Italy· EU contribution €150,000· until Mar 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Immuno-Modulatory Platform for Advanced CLL Therapy (IMPACT)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €150,000· until Mar 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Targeting GAB1: a novel therapeutic strategy for the treatment of leukemias (LeukemiaBlock)

  Masarykova univerzita· Brno, Czechia· EU contribution €150,000· until Feb 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A single-cell-based solution for an early diagnosis of Richter transformation in patients with chronic lymphocytic leukemia (earlyRTdx)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spain· EU contribution €150,000· until Oct 2027

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Translating Epigenetic Memory into Personalized Prognostic Solutions for Chronic Lymphocytic Leukemia (TEMPLe)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spain· EU contribution €150,000· until Jun 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the life histories of chronic lymphocytic leukemia to improve clinical outcome (CLL-STORY)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spain· EU contribution €1,827,291· until Dec 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Making patient-derived tumor organoids a reliable cancer therapy testing platform (TUMORGPLAT)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spain· EU contribution €245,490· until Dec 2029· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Residual disease assessment in hematologic malignancies to improve patient-relevant outcomes across Europe (RESOLVE)

  Martin-Luther-Universitat Halle-Wittenberg· Halle, Germany· EU contribution €8,000,000· until Mar 2029· 8 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  COmputational DEsign for 4D BIOfabrication: harnessing programmable materials for dynamic pre-clinical cancer models (CoDe4Bio)

  Universita Degli Studi di Pavia· Pavia, Italy· EU contribution €1,495,100· until Dec 2027

  The disease is named only in the funder's project summary, not in the title.

10 of 11 running projects, newest first. Listed amounts together: €16.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06839872· AstraZeneca· Updated 5 Jun 2025

  “AstraZeneca has made the decision to cancel the trial.”Registry text, quoted unchanged. Source

• Terminated

  A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

  NCT04477291· Aptose Biosciences Inc.· Updated 7 Mar 2025

  “Change in corporate strategy”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  NCT06846671· BeOne Medicines· Source

• A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT07218341· Eli Lilly and Company· Source

• A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

  NCT02970318· Acerta Pharma BV· Source

• Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

  NCT05294731· BeOne Medicines· Source

• Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL

  NCT07847957· Dana-Farber Cancer Institute· Source

• Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  NCT07739459· The Lymphoma Academic Research Organisation· Source

• A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

  NCT06970743· BeOne Medicines· Source

• Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

  NCT02337829· Acerta Pharma BV· Source

• A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

  NCT03162536· ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)· Source

• ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

  NCT02029443· Acerta Pharma BV· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 1
• Gene Expression Profiling 9
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 3
• Metabolomics 1
• Mass Spectrometry 2
• Flow Cytometry 21
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 9
• Magnetic Resonance Imaging 4
• Machine Learning 10
• Cohort Studies 18
• Genome-Wide Association Study 2

• RNA sequencing detects more challenging cases of somatic hypermutation in the IgHV gene in patients with chronic lymphocytic leukemia.

  Turk J Med Sci, Apr 2026

See which targets of this disease your abstract mentions, and go to the people working on them.